Coty reported Nov. 7 a Q1 revenue decline of 9.2% due to a constellation of supply-chain issues and continued Consumer Beauty weakness. Less than a week later – and two years after its completion of a $12bn merger with P&G’s beauty business – the firm announces Pierre Laubies as CEO, evidently drawn to his experience integrating combined assets at a Dutch coffee company.
[Coty Inc.] will look to newly tapped CEO Pierre Laubies to clean up supply-chain problems that weighed heavily on the firm’s fiscal 2019 first-quarter results, as the company continues to seek sustainable growth in the wake of its 2016 merger with Procter & Gamble Co.’s beauty business.
Laubies, until recently CEO of Dutch coffee company Jacobs Douwe Egberts, also has served stints at Mars, Inc. and Campbell...
Following Energy and Commerce Health Subcommittee hearing about FDA’s human food and tobacco programs on 10 September, gap between what the trade groups, committee leadership and the FDA each want more of doesn’t appear to be shrinking.
The gut’s microbiome will shape future medical advances, offering personalized therapies and prevention strategies for a wide range of diseases.
At one year, TikTok Shop conjures the early days of Amazon, representing the ‘Wild West’ of beauty ecommerce, said co-founders of private label and contract manufacturing company KO-Pack at the IBA Cosmetics Convergence Fall 2024 Virtual Symposium, “The Promise and Pitfalls of TikTok Shop.”
Global beauty giant is working to adapt its approach to the prestige market to meet escalating competition, increased points of sale, and more knowledgeable consumers with new shopping habits, CFO Tracey Travis said at the Barclays Global Consumer Staples Conference.
The gut’s microbiome will shape future medical advances, offering personalized therapies and prevention strategies for a wide range of diseases.
A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.
